Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy
| Autor: | Justin Loke, Marlen Metzner, Eleni Tholouli, Andy Peniket, Charles Craddock, Louise Hopkins, Aimee Jackson, Rebecca H. Boucher, Rebecca Bishop, Mark Drummond, Jiri Pavlu, Sonia Fox, Paresh Vyas |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Adolescent medicine.drug_class Azacitidine Clinical Decision-Making Intensive chemotherapy Romidepsin Young Adult Refractory hemic and lymphatic diseases Internal medicine Depsipeptides Antineoplastic Combined Chemotherapy Protocols medicine Humans Molecular Targeted Therapy neoplasms business.industry Histone deacetylase inhibitor Disease Management Hematology Prognosis Clinical trial Leukemia Myeloid Acute Treatment Outcome Hypomethylating agent Cytogenetic Analysis Female Disease Susceptibility Myeloid leukaemia business medicine.drug |
| Zdroj: | British journal of haematologyReferences. 196(2) |
| ISSN: | 1365-2141 0007-1048 |
| Popis: | Azacitidine (AZA) is important in the management of patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Romidepsin (ROM) is a histone deacetylase inhibitor which synergises with AZA in vitro. The ROMAZA trial established the maximum tolerated dose (MTD) of combined ROM/AZA therapy in patients with AML, as ROM 12 mg/m2 on Days 8 and 15, with AZA 75 mg/m2 administered for 7/28 day cycle. Nine of the 38 (23·7%) patients treated at the MTD were classified as responders by Cycle 6 (best response: complete remission [CR]/incomplete CR n = 7, partial response n = 2). Correlative next-generation sequencing studies demonstrated important insights into therapy resistance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text